SCHEMBL5791770

SCHEMBL5791770

CCN(CC)C(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ PMP22 Q01453 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ DPP4 P27487 4/20 0.42
▸ DPP9 Q86TI2 2/20 0.42
▸ DPP8 Q6V1X1 1/20 0.42
▸ LMNA P02545 1/20 0.35
▸ GRM8 O00222 1/20 0.34
▸ GRM6 O15303 1/20 0.34
▸ GRIN2D O15399 1/20 0.34
▸ GRIN3B O60391 1/20 0.34
▸ GSR P00390 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ GRIK1 P39086 1/20 0.34
▸ GRM5 P41594 1/20 0.34
▸ GRIA1 P42261 1/20 0.34
▸ GRIA2 P42262 1/20 0.34
▸ GRIA3 P42263 1/20 0.34
▸ SLC1A3 P43003 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21312920 0.89 ALOX15 (0.46) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL6742412 0.85 KMT2A (0.48) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL10891103 0.85 KMT2A (0.48) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL1516453 0.84 DPP4 (0.54) BLMKMT2ADPP4DPP9DPP8
SCHEMBL7566248 0.84 DPP4 (0.54) BLMKMT2ADPP4DPP9DPP8
SCHEMBL29751713 0.81 CA1 (0.45) KMT2ADPP4DPP9LMNA
SCHEMBL29357416 0.79 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL564588 0.79 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL4957051 0.79 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5789355 0.79 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF PARABILIS MEDICINES, INC. 2024-04-11 — — US disclosed
EP-1622870-A2 GLUTAMINYL BASED DP IV-INHIBITORS Prosidion Ltd. (GB) 2006-02-08 — — EP disclosed
WO-2004099134-A2 GLUTAMINYL BASED DP IV-INHIBITORS PROSIDION LTD. (GB) 2004-11-18 — — WO disclosed
US-20040229848-A1 Glutaminyl based DP IV-inhibitors PROSIDION LIMITED (GB) 2004-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229848-A1 Glutaminyl based DP IV-inhibitors DPP4, DPP3, DNPEP ALOX15 4131/4885BLM 3796/4885PMP22 2783/4885
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF CTNNB1, APC, CTNNA1 ALOX15 4290/4885BLM 1215/4885PMP22 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback